Tripterygium

PreclinicalSmall molecule

NNanjing University School of Medicine

Tripterygium is one of 143 small molecule programs targeting Proteinuria. It is currently in Preclinical.

Indications

Total Trials

Active Trials

142

Competitors

Pipeline

Status by Indication[3][1]

Indication

ProteinuriaActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

Lupus NephritisActive, not recruiting

Ankylosing SpondylitisActive, not recruiting

PterygiumActive, not recruiting

ProteinuriaPreclinical

Active, not recruiting

Rheumatoid ArthritisPreclinical

Active, not recruiting

Lupus NephritisPreclinical

Active, not recruiting

Ankylosing SpondylitisPhase 2/Phase 3

Active, not recruiting

PterygiumPreclinical

Active, not recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Rituxan

Roche

Preclinical

61 2

Orencia

Bristol-Myers Squibb

Preclinical

47 3

Actemra

Cimzia

30 5

Simponi

Johnson & Johnson

Preclinical

19 6

Arcoxia

Novartis

Preclinical

4 7

Kevzara

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

14 8

Actos

Takeda

Preclinical

2 9

Celexa

AbbVie

Preclinical

1 10

Cataflam

Novartis

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lupus Nephritis1 trial

To Compare the Efficacy and Safety of Tripterygium (TW) Versus AZA in the Maintenance Therapy for Lupus Nephritis

Completed·NNanjing University School of Medicine·N/A·NCT00881309·94 enrolled

Proteinuria1 trial

Prospective Study of TW in the Treatment of LN Type V With Gross Proteinuria

Completed·NNanjing University School of Medicine·N/A·NCT00935389·44 enrolled

Pterygium1 trial

Efficacy Study of Tripterygium Glycoside Combined With Enteral Nutrition in the Treatment of Crohn's Disease for Induction Remission

Unknown status·ZZhu Weiming·N/A·NCT01820247·100 enrolled

Ankylosing Spondylitis1 trial

Clinical Study of Tripterygium Capsule to Treat Early Ankylosing Spondylitis

Unknown status·SSun Yat-sen University·Phase 2/3·NCT00889694·80 enrolled

Rheumatoid Arthritis1 trial

Topical Tripterygium Wilfordii Gel for Moderate Activity Rheumatoid Arthritis

Completed·GGuang'anmen Hospital of China Academy of Chinese Medical Sciences·N/A·NCT02818361·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Tripterygium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tripterygium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tripterygium. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nanjing University School of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNanjing University School of Medicine

Tripterygium

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lupus Nephritis1 trial

Proteinuria1 trial

Pterygium1 trial

Ankylosing Spondylitis1 trial

Rheumatoid Arthritis1 trial

References

Drug Info

Quick Facts

Related News